Pioneering Medicines: Senior Research Associate, In Vivo Pharmacology

Senior Research Associate, In Vivo Pharmacology

Cambridge, MA USA

What if... We could harness the power of Flagship's scientific platforms and create novel treatment options that benefit more patients, sooner?

Pioneering Medicines, a division of Flagship Pioneering, is building a world-class biopharmaceutical R&D capability focused on conceiving and developing life-changing treatments for patients by harnessing the power of Flagship's scientific platforms and applying those innovative approaches to serious diseases with unmet medical need. Unique to Pioneering Medicines' approach is the opportunity to combine platforms to create truly novel and potentially transformative treatments.

We are seeking a Senior Research Associate in the In Vivo Pharmacology group who will be responsible for independently developing and performing studies with animal models across multiple disease areas, including oncology, autoimmunity and metabolism. This individual will collaborate with in vitro biology, translational science and nonclinical groups to help execute on company strategy.

• Support the screening, characterization, and mechanism of action studies for drug candidates of various modalities, including small molecules, biologics and nucleic acids
• Generate high quality data using in vivo models of oncology, autoimmunity and metabolism.
• Monitor animal health, accurately record data and comply with IACUC regulations in regard to animal welfare and care.
• Help develop ex vivo assays in conjunction with translational science to determine relevant pharmacodynamic biomarkers and mechanism of action of targets/programs within PM.
• Collaborate with colleagues within the larger in vivo group, in vitro biology, and translational teams to support PM's daily operations in both the vivarium and the main laboratory.

• BSc or advanced degree in Biology or related disciplines with 2+ years of experience in animal handling within a research setting.
• Expertise in multiple forms of substance administration (e.g., PO, IP, IV, SC)
• Experience in necropsy, tissue collection and processing.
• Demonstrated ability to execute or learn various in vitro and ex vivo assays (e.g., cell culture, ELISA, Flow cytometry)
• Proficient in scientific software (e.g., Excel, Graph Pad Prism, Flow Jo)
• Ability to analyze scientific data and clearly communicate summarized data to internal PM team members and stakeholders.
• Accurately record detailed documentation of experimental results via ELN (Electronic Lab Notebook).
• Ability to operate as part of a team and work with colleagues across the organization to advance projects at all stages.

• Research background in oncology, immunology, or metabolism in an industry or academic setting preferred.
• Previous experience with animal models of metabolism, oncology and autoimmunity preferred.
• Hands-on experience with flow cytometry is a plus.

Flagship Pioneering is a scientific innovation engine that invents and builds companies that change the world. We bring together the greatest scientific minds with entrepreneurial company builders and assemble the capital to allow them to take courageous leaps in human health, sustainability, and beyond.

At Flagship, we recognize there is no perfect candidate. If you have some of the experience listed above but not all, please apply anyway. Experience comes in many forms, skills are transferable, and passion goes a long way. We are dedicated to building diverse and inclusive teams and look forward to learning more about your unique background.

The salary range for this role is $81,000 - $107,250. Compensation for the role will depend on a number of factors, including a candidate's qualifications, skills, competencies, and experience. Pioneering Medicines currently offers healthcare coverage, annual incentive program, retirement benefits and a broad range of other benefits. Compensation and benefits information is based on Pioneering Medicines's good faith estimate as of the date of publication and may be modified in the future.